Division of Hepatology, Department of Upper GI, Karolinska University Hospital, Stockholm, Sweden.
Department of Medicine Huddinge, Unit of Gastroenterology and Rheumatology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Liver Int. 2019 Jun;39(6):1098-1108. doi: 10.1111/liv.14087. Epub 2019 Mar 29.
Non-alcoholic fatty liver disease (NAFLD) is a growing cause of hepatocellular carcinoma (HCC). In NAFLD, HCC occurs more commonly in the absence of cirrhosis compared with other liver diseases; yet, patients with non-cirrhotic NAFLD-HCC are poorly characterized. Here, we characterized a large cohort of HCC cases and assessed the outcomes of patients with non-cirrhotic NAFLD-HCC.
We identified all cases of HCC treated at the Karolinska University Hospital, Stockholm, Sweden from 2004 to 2017. Patient charts were manually reviewed for variable extraction. Cases were followed passively for all-cause and HCC-related mortality until the end of April 2018. Cox regression was performed to estimate mortality rates and identify mortality risk factors in patients with non-cirrhotic NAFLD-HCC.
Totally, 1562 cases with HCC were identified. Of these, 225 (14.4%) had NAFLD-HCC, of which 83 (37%) did not have cirrhosis. Compared with patients with cirrhotic NAFLD-HCC, patients with non-cirrhotic NAFLD-HCC were older (74 vs 70 years, P < 0.001), had a lower prevalence of type 2 diabetes (T2DM) (66% vs 80%, P = 0.02), larger tumours, less frequently underwent liver transplantation (0% vs 11%, P = 0.002), but more frequently underwent resection (35% vs 8%, P < 0.001). Mortality was similar (aHR for non-cirrhotic NAFLD-HCC vs cirrhotic NAFLD-HCC 0.93, 95% CI 0.58-1.51, P = 0.78). Parameters independently associated with increased mortality included the Barcelona Clinic Liver Cancer stage, number of tumours, lower albumin and presence of T2DM.
Patients with non-cirrhotic NAFLD-HCC differ from those with cirrhosis in age, tumour size and allocated treatments. Despite these differences, survival is similar.
非酒精性脂肪性肝病(NAFLD)是肝细胞癌(HCC)日益增长的病因。在 NAFLD 中,与其他肝病相比,HCC 更常发生于无肝硬化的情况下;然而,非肝硬化性 NAFLD-HCC 患者的特征尚未得到充分描述。在此,我们对大量 HCC 病例进行了特征描述,并评估了非肝硬化性 NAFLD-HCC 患者的结局。
我们从 2004 年至 2017 年在瑞典斯德哥尔摩卡罗林斯卡大学医院确定了所有 HCC 病例。通过手动审查患者病历来提取变量。对所有病例进行被动随访,以了解全因和 HCC 相关死亡率,直至 2018 年 4 月底。使用 Cox 回归估计非肝硬化性 NAFLD-HCC 患者的死亡率和识别死亡风险因素。
共确定了 1562 例 HCC 病例,其中 225 例(14.4%)患有 NAFLD-HCC,其中 83 例(37%)无肝硬化。与肝硬化性 NAFLD-HCC 患者相比,非肝硬化性 NAFLD-HCC 患者年龄更大(74 岁比 70 岁,P<0.001),2 型糖尿病(T2DM)患病率较低(66%比 80%,P=0.02),肿瘤较大,肝移植的比例较低(0%比 11%,P=0.002),但接受切除术的比例较高(35%比 8%,P<0.001)。死亡率相似(非肝硬化性 NAFLD-HCC 与肝硬化性 NAFLD-HCC 的 aHR 为 0.93,95%CI 0.58-1.51,P=0.78)。与死亡率增加独立相关的参数包括巴塞罗那临床肝癌分期、肿瘤数量、较低的白蛋白和 T2DM 的存在。
非肝硬化性 NAFLD-HCC 患者与肝硬化性 NAFLD-HCC 患者在年龄、肿瘤大小和治疗分配方面存在差异。尽管存在这些差异,但生存率相似。